a year ago

Owlstone Medical Secures $6.5 Million for Breath Biopsy Platform and TB, HIV Diagnostics

  • Owlstone Medical, a UK-based company specializing in Breath Biopsy® for early disease detection and precision medicine, has raised $6.5 million in funding

  • The round includes a $5 million equity investment to advance Owlstone's Breath Biopsy platform and a $1.5 million grant from the Bill & Melinda Gates Foundation to develop breath-based diagnostics and identify breath biomarkers for tuberculosis (TB) and HIV

  • The equity investment will support advancements of the Breath Biopsy platform, including expansion of the Breath Biopsy VOC Atlas database and development of a remote-use real-time breath analyzer

  • The grant funding will be used to identify breath biomarkers for TB and HIV in partnership with the University of Cape Town and Imperial College and Oxford University, respectively

      • ProblemHealthcare

      "Early disease detection is difficult and often expensive. It's especially challenging in developing countries where access to healthcare is limited."

      Solution

      "Owlstone Medical is developing a breath biopsy platform that uses volatile organic compounds (VOCs) in breath to detect early signs of disease. This can be done with a simple breath test, making it accessible and cost-effective."

      Covered on